Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Cosmo S.p.A.
EIR
•Cosmo S.p.A.•November 10, 2017

Cosmo S.p.A. – FDA EIR, Nov 10, 2017

Record Details

An FDA Pre-Approval Inspection of Cosmo S.p.A. in Lainate, Milan, Italy, was conducted from November 6-10, 2017. The inspection, carried out under Compliance Program Guidance Manual 7346.832, focused on the readiness for commercial manufacturing, conformance to application, and data integrity for their new drug product, (b) (4) Tablet. The company also manufactures LIALDA® and Uceris for the U.S. market. During the previous FDA inspection in 2015, the firm received a VAI classification; all noted deficiencies and required corrective actions from that inspection were confirmed as resolved. However, the current inspection resulted in a one-item FDA Form 483, Inspectional Observations, issued to Mr. Roberto Villa, Chairman. The primary violation identified was inadequate in-process control procedures for the new drug product. Specifically, the Master Batch Record for commercial production of (b) (4) Tablets only required a visual check to confirm (b) (4) after a critical manufacturing step, which the FDA deemed insufficient to ensure product quality, contrary to the more robust testing performed during validation. This observation aligns with regulatory requirements under 21 CFR 211.110(a)(3) regarding control procedures. Additionally, a discussion item concerned an inconsistent and unscientific method for ensuring standard solution samples reached room temperature before use, relying on analysts "feeling the bottle." The firm committed to providing a written response to the FDA 483 observation. For the discussion item, they provided data to establish a consistent equilibration time and plan to update their procedure accordingly.

Company
Cosmo S.p.A.
Inspection date
November 10, 2017
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Roberto Villa (recipient)
  • Roberta Bozzella (company_representative)
  • Davide Malavasi (company_representative)
  • Francesca Rasetti (company_representative)
  • Dien Nguyen (Regulatory Officer I n ve s tig ato r )
View Company Profile

ID · 3c29db55-e6b7-454e-8045-8b6d72081156

Violation Codes2
21 CFR 820.10021 CFR 211.110(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cosmo S.p.A.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.